SV

Street Verdict

Analyst Scorecard

SUPRIYA · NSE

Supriya Lifescience Limited

₹620.15

-0.78% (-₹4.85)

Prev. close

₹625

Volume

1,32,451

Delivery %

53.7%

As of

20 Nov 2026

Price history

₹620.15-₹181.5 (-22.64%) · 3M
18 Aug 2026 → 20 Nov 2026
7008009001,00018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Supriya Lifescience Limited

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals in India and internationally. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides finished formulation products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it develops drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.

Details

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Satish Waman Wagh

Headquarters

Mumbai

Employees

607

Key stats

Market cap

₹6,875.65 Cr

P/E ratio (TTM)

34.4

Dividend yield

0.12%

EPS (TTM)

₹24.81

Beta (1Y · daily vs NIFTY 50)

0.74

Beta (5Y · monthly vs NIFTY 50)

1.05

Shares float

2.55 Cr

EPS · quarter ended Jun 2026

₹2.99

Financial Performance

01 · Financials

0 Cr250 Cr500 Cr750 Cr1000 Cr₹0%10%20%30%FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

0102030₹FY22FY23FY24FY25FY26

03 · Dividend Profile

00111₹0%10%20%30%40%01 Sept 2215 Sept 2320 Sept 2404 Sept 2504 Sept 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-50%0%50%100%FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr500 Cr1000 Cr1500 Cr₹0×0.25×0.5×0.75×FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr500 Cr1000 Cr1500 Cr₹FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-100 Cr0 Cr100 Cr200 Cr₹FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

Total assets for FY22: from the company's own statements, which the series had none for. Current assets for FY22: from the company's own statements, which the series had none for. Equity for FY22: from the company's own statements, which the series had none for. Inventory for FY22: from the company's own statements, which the series had none for. Cash for FY22: from the company's own statements, which the series had none for.

08 · Profit & Loss — as filed

Annual

Line itemFY23FY24FY25FY26
₹470.43 Cr₹580.98 Cr₹706.30 Cr₹839.36 Cr
₹346.94 Cr₹415.29 Cr₹457.82 Cr₹564.13 Cr
Earnings before Tax and exceptional items
₹123.49 Cr₹165.69 Cr₹248.48 Cr₹275.24 Cr
(One time impact of New LabourCodes (Refer Note 38))
———₹-45.80 L
Profit before tax
₹123.49 Cr₹165.69 Cr₹248.48 Cr₹274.78 Cr
₹33.63 Cr₹46.58 Cr₹60.52 Cr₹65.66 Cr
Profit for the year
₹89.86 Cr₹119.11 Cr₹187.96 Cr₹209.12 Cr
₹88.60 Cr₹120.74 Cr₹187.83 Cr₹209.02 Cr
Basic (₹)
11.1614.8023.3525.98
Diluted (*)
11.1614.8023.3525.98

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: standalone statements.

09 · Balance Sheet — as filed

Annual

Line itemFY23FY24FY25FY26
₹355.39 Cr₹523.43 Cr₹675.28 Cr₹824.80 Cr
(a) Inventories
₹115.77 Cr₹85.25 Cr₹118.35 Cr₹159.60 Cr
(i) Loans and Advances
₹54.90 L₹89.70 L₹92.70 L₹56.90 L
(ii) Trade receivables
₹84.66 Cr₹111.68 Cr₹134.36 Cr₹219.45 Cr
(iii) Cash and cash equivalents
₹85.25 Cr₹68.35 Cr₹76.06 Cr₹37.55 Cr
(iv) Bank balances other than (iii) above
₹72.33 Cr₹6.61 Cr₹3.10 Cr₹41.32 Cr
(v) Other Financial Assets
₹6.41 Cr₹4.51 Cr₹71.10 L—
(c) Other current assets
₹99.92 Cr₹120.72 Cr₹108.57 Cr₹73.82 Cr
Total Current Assets
₹464.89 Cr₹398.02 Cr₹442.07 Cr₹532.30 Cr
TOTAL ASSETS
₹820.28 Cr₹921.45 Cr₹1,117.35 Cr₹1,357.11 Cr
₹699.46 Cr₹815.37 Cr₹996.76 Cr₹1,197.73 Cr
(i) Borrowings
——₹5.06 Cr₹5.19 Cr
(ii) Lease Liabilities
₹5.49 Cr₹5.02 Cr——
(b) Provisions
₹5.88 Cr₹80.40 L₹1.32 Cr₹1.90 Cr
(c) Deferred tax Liabilities
₹13.68 Cr₹23.15 Cr₹27.02 Cr₹31.24 Cr
Total Non-Current Liabilities
₹25.04 Cr₹28.98 Cr₹33.39 Cr₹38.33 Cr
(i) Borrowings
₹16.63 Cr—₹32.30 L₹24.60 L
(ii) Lease liabilities
₹35.40 L₹46.80 L—₹17.00 Cr
Other than Micro Enterprises and Small Enterprises
₹64.23 Cr₹59.57 Cr₹74.55 Cr₹93.85 Cr
(iii) Other financial liabilities
₹82.10 L₹1.57 Cr₹1.76 Cr₹2.04 Cr
(b) Provisions
₹83.70 L₹36.50 L₹1.19 Cr₹1.67 Cr
(c) Other current liabilities
₹12.92 Cr₹15.13 Cr₹9.37 Cr₹6.24 Cr
Total Current Liabilities
₹95.78 Cr₹77.11 Cr₹87.19 Cr₹121.04 Cr
TOTAL EQUITY AND LIABILITIES
₹820.28 Cr₹921.45 Cr₹1,117.35 Cr₹1,357.11 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: standalone statements.

10 · Cash Flow Statement — as filed

Annual

Line itemFY24FY25FY26
₹-82.63 Cr₹4.20 Cr₹-28.70 L
₹113.31 Cr₹164.68 Cr₹185.77 Cr
₹-173.57 Cr₹-152.24 Cr₹-176.17 Cr
₹-22.36 Cr₹-8.23 Cr₹-9.88 Cr
Cash and Cash Equivalents at the end of previous period
₹157.58 Cr₹74.96 Cr₹79.15 Cr
Cash and Cash Equivalents as at the end of the reporting period
₹74.96 Cr₹79.15 Cr₹78.87 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: standalone statements.

11 · Shareholding Pattern

NSE, quarterly

Line itemDec 21–Dec 22(6Q)Mar 23Jun 23–Jun 26(13Q)
Promoter68.24%68.28%68.30%
Public31.76%31.72%31.70%
Employee trusts0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Supriya Lifescience Limited₹6,724.34 Cr₹832.833.95.6117.5%0.00+18.1%+6.1%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

2 indices

SUPRIYA

Supriya Lifescience Ltd Q2 FY27 Profit Falls 42% Amid Margin Reset

Multibagg AI · 9 days ago

SUPRIYA

Supriya Lifescience Reports 14.8% Revenue Growth In H1 FY27

Supriya Lifescience Ltd. reported a 14.8% year‑on‑year revenue rise to Rs 396.04 crore in H1 FY27, driven by higher sales in Europe and expanding vitamin and analgesic segments. However, EBITDA and PAT margins fell sharply due to regulatory shifts in Latin America, higher raw‑material costs, and ramp‑up expenses at its Ambernath plant.